
Investments
85Portfolio Exits
22Funds
6About MVM Partners
MVM Partners is a venture capital firm. It invests in high-growth healthcare businesses and has a broad, global investment outlook spanning medical technology, pharmaceuticals, diagnostics, contract research and manufacturing, digital health, and other sectors of healthcare. The company was founded in 1997 and is based in London, U.K.
Latest MVM Partners News
Nov 28, 2023
Gynesonics – a women’s healthcare company focused on developing minimally invasive solutions for symptomatic uterine fibroids – recently announced that it has secured an incremental $42.5 million in financing (total of $67.2 million inclusive of initial April 2023 financing). The funding round was led by existing Gynesonics investors Amzak Health, Endeavour Vision, Kaiser Permanente Ventures, Runway Growth Capital, and Bain Capital, with new investments coming from MVM Partners and several other healthcare investors excited about Gynesonics’ commercial advances. As pioneers in women’s health, Gynesonics is committed to developing and delivering minimally invasive, incision-free, uterus-preserving, transcervical technologies for diagnostic and therapeutic applications. And Gynesonics’ flagship product – the Sonata System – is the first FDA-cleared medical device for diagnostic intrauterine imaging and transcervical treatment of symptomatic uterine fibroids, a medical condition affecting roughly 80% of adult women. Before the Sonata System, fibroid removal was limited to invasive medical procedures, like a hysterectomy, which carries greater risk and significantly more recovery time. KEY QUOTES: “Gynesonics continues to lay a strong foundation for success, having achieved a number of important commercial milestones in the most recent quarters. The company is very well positioned to continue the acceleration of its growth going forward. Amzak Health and our fellow Gynesonics investors are very excited about the company’s prospects to become the leading long-term solution in the treatment of symptomatic fibroids.” — Joyce Erony, General Partner, Amzak Health “Uterine fibroids cause suffering to millions of women. MVM is glad to support Gynesonics in offering a uterus-preserving, incisionless alternative to hysterectomy and myomectomy.” — Hugo Harrod of MVM Partners “This funding will enable Gynesonics to continue to expand commercial operations and provide millions of patients suffering from symptomatic fibroids a safe and efficacious minimally invasive treatment. With 275M+ U.S. covered lives (including 19 of the top 20 commercial payers) covering Sonata and our new Category 1 code going live in January, we are excited to accelerate our commercial efforts in the U.S. as well as Europe.” — Skip Baldino, President and CEO of Gynesonics Sponsors
MVM Partners Investments
85 Investments
MVM Partners has made 85 investments. Their latest investment was in BioProtect as part of their Series E on September 9, 2023.

MVM Partners Investments Activity

Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
9/27/2023 | Series E | BioProtect | $28M | Yes | 1 | |
7/13/2023 | Series C | CurvaFix | $39M | Yes | Sectoral Asset Management, and Undisclosed Investors | 6 |
6/6/2023 | Series H | Vertos Medical | $26M | No | 3 | |
5/30/2023 | Series A | |||||
4/11/2023 | Series H |
Date | 9/27/2023 | 7/13/2023 | 6/6/2023 | 5/30/2023 | 4/11/2023 |
---|---|---|---|---|---|
Round | Series E | Series C | Series H | Series A | Series H |
Company | BioProtect | CurvaFix | Vertos Medical | ||
Amount | $28M | $39M | $26M | ||
New? | Yes | Yes | No | ||
Co-Investors | Sectoral Asset Management, and Undisclosed Investors | ||||
Sources | 1 | 6 | 3 |
MVM Partners Portfolio Exits
22 Portfolio Exits
MVM Partners has 22 portfolio exits. Their latest portfolio exit was Patient Connect on December 22, 2021.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
12/22/2021 | Acquired | 1 | |||
11/4/2021 | IPO - II | Public | 6 | ||
10/15/2021 | IPO | Public | 1 | ||
Date | 12/22/2021 | 11/4/2021 | 10/15/2021 | ||
---|---|---|---|---|---|
Exit | Acquired | IPO - II | IPO | ||
Companies | |||||
Valuation | |||||
Acquirer | Public | Public | |||
Sources | 1 | 6 | 1 |
MVM Partners Acquisitions
1 Acquisition
MVM Partners acquired 1 company. Their latest acquisition was AmbioPharm on November 20, 2014.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
---|---|---|---|---|---|---|
11/20/2014 | Private Equity | Acq - Fin | 2 |
Date | 11/20/2014 |
---|---|
Investment Stage | Private Equity |
Companies | |
Valuation | |
Total Funding | |
Note | Acq - Fin |
Sources | 2 |
MVM Partners Fund History
6 Fund Histories
MVM Partners has 6 funds, including MVM VI.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
---|---|---|---|---|---|
11/14/2022 | MVM VI | $500M | 1 | ||
1/8/2020 | MVM V | ||||
5/3/2016 | MVM IV | ||||
1/1/2008 | MVM Fund III | ||||
1/1/2002 | MVM International Life Sciences Fund |
Closing Date | 11/14/2022 | 1/8/2020 | 5/3/2016 | 1/1/2008 | 1/1/2002 |
---|---|---|---|---|---|
Fund | MVM VI | MVM V | MVM IV | MVM Fund III | MVM International Life Sciences Fund |
Fund Type | |||||
Status | |||||
Amount | $500M | ||||
Sources | 1 |
MVM Partners Team
1 Team Member
MVM Partners has 1 team member, including current Founding Partner, Stephen Reeders.
Name | Work History | Title | Status |
---|---|---|---|
Stephen Reeders | Founding Partner | Current |
Name | Stephen Reeders |
---|---|
Work History | |
Title | Founding Partner |
Status | Current |
Compare MVM Partners to Competitors
Kjaya is a company that received a SBIR Phase I grant for a project entitled: Semi-Autonomous Adaptive Neural and Genetic Segmentation of Medical Images. Their Phase I project will implement a physician-assisted, real-time adaptive system for the segmentation of anatomical structures in 3D medical image data. Medical image segmentation seeks to change the representation of an anatomical structure, making it more easily analyzed. Because of the extreme variability of these structures in biological systems, current idiosyncratic manual methods currently in use are tedious, time consuming, and error prone. Image segmentation cannot in general be programmatically solved. The proposed system is a Neural Network (NN) based adaptation of the individual data using parallel Graphics Processing Units (GPUs) and coupled with a Genetic Algorithm (GA) based adaptation across GPU cores. The system will build a diagnostically useful segmentation of the anatomical feature within seconds from an area of interest outlined by a physician using a Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scan. Fast growth in medical imaging overwhelms available diagnosticians. An intuitive and inexpensive system to quickly and accurately deliver diagnostic relevant segmentation of medical images offers tremendous commercial value. Currently, each scan requires approximately 50 minutes of manual preparation. The diagnosis and treatment of an estimated 20 percent of diseases benefit from medical imaging. Newer scanning technologies have increased in resolution, but such techniques have not made segmenting easier or faster. The proposed method will enable more diagnostics to be done with the quality controlled directly by physicians.
3i US Investors is a multinational private equity and venture capital company that manages to focus on four core sectors including business and technology services, consumer, healthcare and industrial. It is based in London, England.

Sciety is an investment syndicate that offers capital market services with a focus on life science. It specializes in investment, finance, market analysis, and more. It is based in Stockholm, Sweden.
Syncona Partners (LON: SYNC) is an investment company. The company offers services that include founding, building, and funding companies. It makes investments in life sciences companies including gene therapy, cell therapy, biologics, and small molecule fields. The company was founded in 2012 and is based in London, U.K.
M2m Imaging is a company focused on the development and manufacturing of products for pre-clinical imaging in the healthcare industry. The company's main offerings include custom developed RF coils for magnetic resonance imaging and physiological monitoring devices. These products are primarily used in the research and development sector of the healthcare industry. It was founded in 1999 and is based in Cleveland, Ohio.
Medilink UK is a membership-based professional association and consulting firm that focuses on life science company growth. It uses the combined strengths of its regional partners to assist the growth and development of the life sciences commercial, academic, and clinical communities across the UK. It provides services to the medical device, pharmaceutical, and biotechnology industries. It was founded in 2005 and is based in Nottingham, United Kingdom.
Loading...